{"disease":{"id":"recurrent-solid-neoplasm","name":"recurrent solid neoplasm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02474160","title":"Collection and Storage of Tissue and Blood Samples From Patients With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Cancer Institute LAO","has_results":false},{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06295965","title":"Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05455606","title":"Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1284,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT04960787","title":"Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":331,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT03604315","title":"Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03760952","title":"Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling","phase":"","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Immatics US, Inc.","has_results":false},{"nct_id":"NCT05058339","title":"Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04062552","title":"Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":208,"lead_sponsor_name":"University of Rochester NCORP Research Base","has_results":false},{"nct_id":"NCT04871477","title":"Adoption of Audio Recording in the Outpatient Supportive Care Center","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04090619","title":"Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":192,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03035409","title":"Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":129,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT00939770","title":"Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT05059678","title":"Parenting Support Intervention for Families Coping With Metastatic or Locally Recurrent Solid Tumor Diagnosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04693468","title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":111,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02867592","title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":109,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03927885","title":"Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03583255","title":"Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":99,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00892736","title":"Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06223542","title":"Studying TAK-243 in Patients With Advanced Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":95,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04901702","title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT03212274","title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":89,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01012817","title":"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05286801","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":86,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02159989","title":"Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":83,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06620302","title":"Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":81,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02408861","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05101356","title":"A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":77,"lead_sponsor_name":"Tianhong Li","has_results":false},{"nct_id":"NCT02095132","title":"Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06126276","title":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04840589","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05857969","title":"Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":65,"lead_sponsor_name":"Florida International University","has_results":false},{"nct_id":"NCT03502733","title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04870944","title":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02323880","title":"Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT07174661","title":"Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Advanced Solid Tumors and High-Grade Brain Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02142803","title":"TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02451553","title":"Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT01709435","title":"Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02116777","title":"Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02188264","title":"Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06320405","title":"Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01822522","title":"Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04007744","title":"Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}